Sadie P. Antine

Sadie P. Antine

Auto-generated profile, based on publicly available information

Sadie P. Antine

Department of Microbiology, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
ALAzita Leavitt
Azita Leavitt
EYErez Yirmiya
Erez Yirmiya
GAGil Amitai
Gil Amitai
ALAllen Lu
Allen Lu
JGJeremy Garb
Jeremy Garb
RSRotem Sorek
Rotem Sorek

22 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
EYErez Yirmiya
Erez Yirmiya
ALAzita Leavitt
Azita Leavitt
ALAllen Lu
Allen Lu
ARAdelyn E. Ragucci
Adelyn E. Ragucci
CACarmel Avraham
Carmel Avraham
RSRotem Sorek
Rotem Sorek

22 November 2023 in Nature
Verified
Journal Article
Open access
PDF file
SASadie P. Antine
Sadie P. Antine
AJAlex G. Johnson
Alex G. Johnson
SMSarah E. Mooney
Sarah E. Mooney
ALAzita Leavitt
Azita Leavitt
MMMegan L. Mayer
Megan L. Mayer
PKPhilip J. Kranzusch
Philip J. Kranzusch
Bacteria encode hundreds of diverse defence systems that protect them from viral infection and inhibit phage propagation1–5. Gabija is one of the most prevalent anti-phage defence systems, occurring in more than 15% of all sequenced bacterial and archaeal genomes1,6,7, but the molecular basis of how Gabija defends cells from viral infection remains poorly understood. Here we use X-ray crystallography and cryo-electron microscopy (cryo-EM) to define how Gabija proteins assemble into a supramolecular complex of around 500 kDa that degrades phage DNA. Gabija protein A (GajA) is a DNA endonuclease that tetramerizes to form the core of the anti-phage defence complex. Two sets of Gabija protein B (GajB) dimers dock at opposite sides of the complex and create a 4:4 GajA–GajB assembly (hereafter, GajAB) that is essential for phage resistance in vivo. We show that a phage-encoded protein, Gabija anti-defence 1 (Gad1), directly binds to the Gabija GajAB complex and inactivates defence. A cryo-EM structure of the virally inhibited state shows that Gad1 forms an octameric web that encases the GajAB complex and inhibits DNA recognition and cleavage. Our results reveal the structural basis of assembly of the Gabija anti-phage defence complex and define a unique mechanism of viral immune evasion.

28 January 2026 in Nature
Verified
Journal Article
Open access
PDF file
MSMolly R. Sargen
Molly R. Sargen
SASadie P. Antine
Sadie P. Antine
GGGrzegorz Grabe
Grzegorz Grabe
GAGabriella Antonellis
Gabriella Antonellis
ARAdelyn E. Ragucci
Adelyn E. Ragucci
SHSophie Helaine
Sophie Helaine
Most bacterial pathogens are polylysogens, harbouring multiple vertically transmitted prophages1,2,3. These prophages enhance bacterial pathogenicity and survival by encoding virulence factors and anti-phage defence systems while retaining the capacity for horizontal transfer. Thus, prophage-encoded anti-phage defences must block propagation of external phages without inhibiting the spread of the prophages that encode them. Here we identify HepS—an abortive infection system encoded on the Gifsy-1 prophage constituted of a single HEPN domain protein—which restricts phages of the Siphoviridae family. We demonstrate that in its native host context of Salmonella enterica serovar Typhimurium, HepS both senses phage infection and enacts abortive infection. Structures of HepS reveal a tetrameric nuclease complex that undergoes allosteric activation upon recognition of Siphoviridae tail tip proteins during production of new phage particles. Once activated, HepS cleaves specific transfer RNA anticodon loops and arrests phage replication. Gifsy-1, a Siphoviridae itself, evades self-targeting by expressing a tail tip variant that does not trigger HepS, as do co-resident Siphoviridae prophages Gifsy-2 and Gifsy-3. This evasion permits Gifsy-1 to spread despite encoding HepS. These findings reveal a mechanism by which a prophage defends the host while maintaining its propagation abilities.

1 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SASadie P. Antine
Sadie P. Antine
AJAlex G. Johnson
Alex G. Johnson
SMSarah E. Mooney
Sarah E. Mooney
ALAzita Leavitt
Azita Leavitt
MMMegan L. Mayer
Megan L. Mayer
PKPhilip J. Kranzusch
Philip J. Kranzusch
Bacteria encode hundreds of diverse defense systems that protect from viral infection and inhibit phage propagation 1–5 . Gabija is one of the most prevalent anti-phage defense systems, occurring in >15% of all sequenced bacterial and archaeal genomes 1,6,7 , but the molecular basis of how Gabija defends cells from viral infection remains poorly understood. Here we use X-ray crystallography and cryo-EM to define how Gabija proteins assemble into an ∼500 kDa supramolecular complex that degrades phage DNA. Gabija protein A (GajA) is a DNA endonuclease that tetramerizes to form the core of the anti-phage defense complex. Two sets of Gabija protein B (GajB) dimers dock at opposite sides of the complex and create a 4:4 GajAB assembly that is essential for phage resistance in vivo . We show that a phage-encoded protein Gabija anti-defense 1 (Gad1) directly binds the Gabija GajAB complex and inactivates defense. A cryo-EM structure of the virally inhibited state reveals that Gad1 forms an octameric web that encases the GajAB complex and inhibits DNA recognition and cleavage. Our results reveal the structural basis of assembly of the Gabija anti-phage defense complex and define a unique mechanism of viral immune evasion.

26 May 2026 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Open access
JCJill E Chrencik
Jill E Chrencik
HSHua-Poo Su
Hua-Poo Su
YLYacob Gomez Llorente
Yacob Gomez Llorente
RPRachel L. Palte
Rachel L. Palte
DKDaniel J. Klein
Daniel J. Klein
SGSandra B. Gabelli
Sandra B. Gabelli
Structural biology has fundamentally influenced pharmaceutical research and development at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, progressing from pioneering macromolecular crystallography in the 1980s to a fully integrated platform that today encompasses X-ray crystallography, cryo-electron microscopy, micro-electron diffraction and cryo-electron tomography. In this review, we present a comprehensive overview of how these complementary methods have advanced drug discovery across diverse therapeutic areas. We illustrate how atomic to cellular structural insights inform drug discovery and development, from target identification and validation, hit finding, lead identification through lead optimization and clinical progression. Furthermore, we describe how structural biology techniques aid in formulation strategies of antibodies and vaccines. Finally, we highlight the growing integration of ex situ and in situ approaches as a paradigm shift towards elucidating drug mechanisms in native cellular contexts, a transition poised to accelerate the discovery and development of next-generation therapeutics.